Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies

Julie K. Jadlowsky, Elizabeth O. Hexner, Amy Marshall, Stephan A. Grupp, Noelle V. Frey, James L. Riley, Elizabeth Veloso, Holly McConville, Walter Rogal, Cory Czuczman, Wei‐Ting Hwang, Yimei Li, Rachel Leskowitz, Olivia Farrelly, Jayashree Karar, Shannon Christensen, Julie S. Barber-Rotenberg, Avery L. Gaymon, Naomi Aronson, Wendy Bernstein, J. Joseph Melenhorst, Aoife M. Roche, J.K. Everett, Sonja A. Zolnoski, Alexander McFarland, Shantan Reddy, Angelina Petrichenko, Emma J. Cook, Carole Lee, Vanessa Gonzalez, Kathleen A. Alexander, Irina Kulikovskaya, Ángel Ramírez-Fernández, Janna Minehart, Marco Ruella, Saar Gill, Stephen J. Schuster, Adam D. Cohen, Alfred L. Garfall, Payal D. Shah, David L. Porter, Shannon L. Maude, Bruce L. Levine, Don L. Siegel, Anne Chew, S.J. McKenna, Lester Lledo, Megan M. Davis, Gabriela Plesa, Friederike Herbst, Edward A. Stadtmauer, Pablo Tebas, Amanda M. DiNofia, A. Haas, Naomi B. Haas, Regina M. Myers, Donald M. O’Rourke, Jakub Svoboda, János L. Tanyi, Richard Aplenc, Jeffrey M. Jacobson, Andrew H. Ko, Roger B. Cohen, Carl H. June, Frederic D. Bushman, Joseph A. Fraietta